- Home
- LFCR vs NGEN Comparison
LFCR vs NGEN Comparison
Compare LFCR & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LFCR | NGEN |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.9M | 200.0M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LFCR | NGEN |
|---|---|---|
| Price | $4.65 | $2.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.00 | ★ $18.00 |
| AVG Volume (30 Days) | 122.5K | ★ 426.2K |
| Earning Date | 05-06-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $557,559,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $3.63 | $1.58 |
| 52 Week High | $8.98 | $5.93 |
Technical Indicators
Market Signals| Indicator | LFCR | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 70.20 |
| Support Level | $4.63 | $1.85 |
| Resistance Level | $5.21 | $2.22 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 46.10 | 91.58 |
Price Performance
Historical ComparisonAbout LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.